Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: J Neuroimmune Pharmacol. 2020 Nov 22;16(3):667–678. doi: 10.1007/s11481-020-09972-1

Fig. 6. DHED treatment protects against MPTP-induced behavioral impairments.

Fig. 6

Mice (C57BL/6; WT) were assessed on a battery of behavioral tests to assess motor function. (A) Rotarod latency to fall from an accelerating rotating rod was measured in saline-injected mice, MPTP-injected mice, MPTP-injected mice treated with 50 and 100 μg/kg DHED. In each trial, n=6 mice for each condition; 3 trials conducted. MPTP treated WT mice had a shorter latency to fall in comparison to saline-treated WT mice and significantly recovered in DHED treated mice (100μg/kg) as compared to only MPTP treated mice. (B) The grip strength decreased significantly in the MPTP injected animals as compared to control animals. Treating the animals with DHED followed by MPTP injections has improved motor deficit as compared with MPTP only injected group. (C) Raised-beam tasks assessed the ability of mice to traverse narrow beams to reach a dark box. Overall, MPTP-treated mice moved slower than saline-treated WT mice, whereas, DHED treated mice with a dose of 100μg/kg significantly took less time to cross the traverse narrow beams to reach a dark box as compared to the MPTP treated group. Data were analyzed by one-way ANOVA analysis. The values are expressed as mean ± SEM *P < 0.05, **P<0.01.